A Phase I/II Open-Label, Dose Escalation and Dose Expansion Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of AZD6621, a T Cell-Engaging Antibody that Targets STEAP2, CD3, and CD8 in Adult Participants with Metastatic Prostate Cancer (ACTIVATED-4-PC)

Clinical Trial Information

Trial Phone: 321-841-7246

Principal Investigator: Jad Chahoud, MD

Phase: I/II

Age Group: ADULTOLDER_ADULT

ClinicalTrials.gov ID: NCT07192614

Objective

This study will monitor how many participants experience side effects, from mild to serious, during treatment, including any changes in labs, vital signs, heart tests, or physical exams, as well as any early toxicities related to dosing. The study will also measure how well the treatment works by tracking PSA response in participants.

Share:

Related Clinical Trials

A Phase 3, Randomized, Multicenter, Open-Label Study of IDRX-42 (GSK6042981) versus Sunitinib in Participants with Metastatic and/or Unresectable Gastrointestinal Stromal Tumors (GIST) after Imatinib Therapy (StrateGIST 3)
A Phase 3, Open Label, Multicenter, Randomized Study of First Line Tarlatamab in Combination with Durvalumab, Carboplatin and Etoposide Versus Durvalumab, Carboplatin and Etoposide in Untreated Extensive Stage Small-Cell Lung Cancer (DeLLphi-312)
RETROSPECTIVE REVIEW OF PLAVIX RESISTANCE IN CENTRAL FLORIDA PATIENTS UNDERWENT TRANSCAROTID ARTERY REVASCULARIZATION (TCAR)
Are Premature Infants with Bronchopulmonary Dysplasia Requiring Tracheostomy and Ventilation at Increased Risk of Atypical Craniosynostosis?